Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Terminated × Hyperuricemia × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Completed 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 79 Breast Neoplasms 74 Neoplasms 71 Prostatic Neoplasms 47 Lung Neoplasms 38 Neoplasm Metastasis 34 Leukemia, Myeloid, Acute 31 Colorectal Neoplasms 30 Pain 24 Ovarian Neoplasms 23 Multiple Myeloma 23 Head and Neck Neoplasms 23 Colonic Neoplasms 22 Carcinoma, Hepatocellular 22 Lymphoma 21 Pancreatic Neoplasms 20 Leukemia 20 Lymphoma, Non-Hodgkin 18 Lymphoma, Follicular 18 Recurrence 17 Rectal Neoplasms 17 Melanoma 17 Urinary Bladder Neoplasms 16 Lymphoma, Large B-Cell, Diffuse 15 Leukemia, Lymphocytic, Chronic, B-Cell 14 Stomach Neoplasms 13 Precursor Cell Lymphoblastic Leukemia-Lymphoma 13 Brain Neoplasms 13 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12 Squamous Cell Carcinoma of Head and Neck 11

Interventions

rasburicase 1 Allopurinol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00607152 2014-05-08

Rasburicase (Fasturtec) Registration Trial

Sanofi

Phase 3 Terminated

Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡